NCT02656069View on ClinicalTrials.gov

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

August 14, 2017

Study Completion Date

September 25, 2017

Conditions
HypoglycemiaDiabetes Mellitus, Type 1
Interventions
DRUG

G-Pen (glucagon injection)

1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector

DRUG

Lilly Glucagon (glucagon injection [rDNA origin])

1 mg of Lilly glucagon reconstituted from lyophilized powder

Trial Locations (7)

35294

University of Alabama at Birmingham, Birmingham

78229

Clinical Trials of Texas, Inc., San Antonio

91911

ProSciento, Inc., Chula Vista

92025

AMCR Institute, Escondido

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Research, Renton

M4G 3E8

LMC Diabetes & Endocrinology, Toronto

Sponsors
All Listed Sponsors
lead

Xeris Pharmaceuticals

INDUSTRY